Dimension scores are derived from public data and fields; weighted into the composite. Reference only.
This website appears to be the China official site of a pharmaceutical CDMO service provider. The company description in the main content corresponds to Chongqing Porton Pharma Solutions Ltd. (Porton, stock code 300363). It is not a general healthcare services platform; rather, it targets global pharmaceutical companies, biotech firms, and research institutions, offering outsourced R&D, process development, and manufacturing solutions across the full drug lifecycle, from preclinical research to commercial launch.
The site highlights four major service lines: small-molecule drug CDMO, peptide and oligonucleotide drug CDMO, protein and conjugated drug CDMO, and cell and gene therapy CDMO. It also lists technical capabilities such as drug crystallization, biocatalysis, metal catalysis, continuous reactions, supercritical fluid chromatography, milling/micronization, and chemical engineering. The content also covers global footprint, corporate governance, ESG, investor relations, news and media, case studies, white papers, and webinars, making it suitable for potential clients conducting initial supplier research.
No standard pricing or packages are disclosed on the site. Pharmaceutical CDMO services are typically highly customized B2B engagements. Quotes depend on factors such as drug type, development stage, process complexity, batch size, GMP requirements, target regulatory markets, and delivery timeline, and usually require assessment through discussions with the commercial or technical team.
The main strengths are its comprehensive service chain, covering everything from small molecules to emerging biologics, and its relatively broad global R&D and manufacturing footprint. The site also mentions experience with regulatory inspections by agencies such as the US FDA and EMA, which helps build compliance confidence. The downsides are that the captured page text contains a large amount of garbled content and suspicious replacement text such as “AG公司,” which undermines the professional image of the official site. It also lacks more detailed case studies, service workflows, delivery timelines, and quality system explanations, so visitors would still need offline communication to confirm key details.
This site is suitable for innovative drug companies, biotech firms, multinational pharmaceutical companies, research institutions, and teams needing outsourced R&D and manufacturing for APIs, formulations, peptides, oligonucleotides, ADCs, or cell and gene therapies. It is not intended for ordinary patients seeking medical consultation or purchasing medicines.
The domain has ICP filing and public security registration information. Based on the main content, it appears to provide official-site content for users in China, so it is expected to be directly accessible from mainland China. However, due to abnormal text quality on the page, it is advisable to further verify authenticity through the official filing entity, company announcements, or known official domains.
⚠ This review is compiled from public sources and does not constitute a purchase recommendation. Verify all facts on the vendor's official site. Verify on haofamuye.com official site.
haofamuye.com is an China Health provider. TG4G tracks its product information, an overall rating of 2.0/10, and a China-accessibility score of China direct-connect friendly. Click "Visit Official Site" to reach haofamuye.com directly.